FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903313471> ?p ?o ?g. }

• W2903313471 endingPage "27" @default.
• W2903313471 startingPage "21" @default.
• W2903313471 abstract "Introduction. Chronic venous diseases are one of the urgent problems of modern medicine. Recent studies have shown high significance of endothelial dysfunction (ED) and oxidative stress in their pathogenesis. For the correction of the occurring changes, drugs of the flavonoid group, particularly diosmin and hesperidin, are currently used. Numerous studies have confirmed a vast range of biological effects of diosmin; however, there are only sporadic data on its endothelium protective effects.&#x0D; Materials and methods. The study was performed in 70 white mature male rats of Wistar line, weighing 180-220 g. ED simulation was performed using non-selective blocker of NO-synthase N-nitro-L-arginine methyl ester (L-NAME). Functional vascular tests and biochemical markers were used to determine a degree of correction of functional disorders. An anti-inflammatory effect of Detralex 1000 mg was estimated in 10 mature albino rabbits weighing 2800 - 3200 g by using o-xylene. The study of the venotonic property of the drug was carried out in the experiment in an isolated segment of the rats’ portal vein with Ca2+ solutions at a concentration of 0.08-1.75 mcM. The histologic specimens were prepared in accordance with the generally accepted methods.&#x0D; Results and discussion. The administration of the test drug did not lead to a statistically significant decrease in blood pressure in the conditions of L-NAME-induced ED. However, there was a dose-dependent statistically significant decrease in the coefficient of ED (CED), which indicates a positive endothelium protective effect. Course administration of Detralex 1000 mg leads to a significant dose-dependent correction of platelet aggregation disorders, which is manifested in the extended aggregation time. The results of studying an anti-inflammatory activity of the drug showed a decrease in the size of spots caused by the application of o-xylene, and the extention of the time interval before their onset. Studying a Ca2+-mediated smooth muscle response showed that the vein contractile force reaches its maximum at a higher dosage of the drug with a lower concentration of Ca2+. In the morphological study of the stomach wall, small and large intestine of the intact rats and rats receiving a course of Detralex 1000 mg, there were no inflammatory changes in the mucosa of the comparison group.&#x0D; Conclusions. The study found that Detralex 1000 mg significantly reduces the ED coefficient and slows platelet aggregation against the background of L-NAME-induced ED; the efficacy is dose-dependent. Detralex 1000 mg dose-dependently reduces vascular permeability disorders caused by the application of o-xylene. The test drug has a Ca2+-mediated mechanism of increasing the contractile activity of the venous wall. It was found that the course administration of the drug per os has no local irritative effect." @default.
• W2903313471 created "2018-12-11" @default.
• W2903313471 creator A5005484012 @default.
• W2903313471 creator A5014803659 @default.
• W2903313471 creator A5037110251 @default.
• W2903313471 creator A5044778727 @default.
• W2903313471 date "2018-12-06" @default.
• W2903313471 modified "2023-09-25" @default.
• W2903313471 title "Evaluation of pharmacological correction of L-name-induced endothelial dysfunction, platelet aggregation and venous tone with diosmin Detralex 1000 mg" @default.
• W2903313471 cites W192471487 @default.
• W2903313471 cites W1991774590 @default.
• W2903313471 cites W2004107353 @default.
• W2903313471 cites W2033925341 @default.
• W2903313471 cites W2075409030 @default.
• W2903313471 cites W2095916131 @default.
• W2903313471 cites W2102689108 @default.
• W2903313471 cites W2108179075 @default.
• W2903313471 cites W2256286373 @default.
• W2903313471 cites W2287215836 @default.
• W2903313471 cites W2336832507 @default.
• W2903313471 cites W2522961318 @default.
• W2903313471 cites W2733972101 @default.
• W2903313471 cites W2743404527 @default.
• W2903313471 cites W2782335576 @default.
• W2903313471 cites W2793298901 @default.
• W2903313471 cites W2888793780 @default.
• W2903313471 cites W4245307147 @default.
• W2903313471 cites W4297924666 @default.
• W2903313471 doi "https://doi.org/10.3897/rrpharmacology.4.31748" @default.
• W2903313471 hasPublicationYear "2018" @default.
• W2903313471 type Work @default.
• W2903313471 sameAs 2903313471 @default.
• W2903313471 citedByCount "3" @default.
• W2903313471 countsByYear W29033134712019 @default.
• W2903313471 countsByYear W29033134712022 @default.
• W2903313471 crossrefType "journal-article" @default.
• W2903313471 hasAuthorship W2903313471A5005484012 @default.
• W2903313471 hasAuthorship W2903313471A5014803659 @default.
• W2903313471 hasAuthorship W2903313471A5037110251 @default.
• W2903313471 hasAuthorship W2903313471A5044778727 @default.
• W2903313471 hasBestOaLocation W29033134713 @default.
• W2903313471 hasConcept C126322002 @default.
• W2903313471 hasConcept C142724271 @default.
• W2903313471 hasConcept C204787440 @default.
• W2903313471 hasConcept C2776128092 @default.
• W2903313471 hasConcept C2776151105 @default.
• W2903313471 hasConcept C2776992346 @default.
• W2903313471 hasConcept C2780035454 @default.
• W2903313471 hasConcept C2780565469 @default.
• W2903313471 hasConcept C2780972559 @default.
• W2903313471 hasConcept C519581460 @default.
• W2903313471 hasConcept C71924100 @default.
• W2903313471 hasConcept C98274493 @default.
• W2903313471 hasConceptScore W2903313471C126322002 @default.
• W2903313471 hasConceptScore W2903313471C142724271 @default.
• W2903313471 hasConceptScore W2903313471C204787440 @default.
• W2903313471 hasConceptScore W2903313471C2776128092 @default.
• W2903313471 hasConceptScore W2903313471C2776151105 @default.
• W2903313471 hasConceptScore W2903313471C2776992346 @default.
• W2903313471 hasConceptScore W2903313471C2780035454 @default.
• W2903313471 hasConceptScore W2903313471C2780565469 @default.
• W2903313471 hasConceptScore W2903313471C2780972559 @default.
• W2903313471 hasConceptScore W2903313471C519581460 @default.
• W2903313471 hasConceptScore W2903313471C71924100 @default.
• W2903313471 hasConceptScore W2903313471C98274493 @default.
• W2903313471 hasIssue "4" @default.
• W2903313471 hasLocation W29033134711 @default.
• W2903313471 hasLocation W29033134712 @default.
• W2903313471 hasLocation W29033134713 @default.
• W2903313471 hasLocation W29033134714 @default.
• W2903313471 hasLocation W29033134715 @default.
• W2903313471 hasOpenAccess W2903313471 @default.
• W2903313471 hasPrimaryLocation W29033134711 @default.
• W2903313471 hasRelatedWork W1414492878 @default.
• W2903313471 hasRelatedWork W1573451568 @default.
• W2903313471 hasRelatedWork W1973018488 @default.
• W2903313471 hasRelatedWork W1973610105 @default.
• W2903313471 hasRelatedWork W1974257568 @default.
• W2903313471 hasRelatedWork W2004496090 @default.
• W2903313471 hasRelatedWork W2053705719 @default.
• W2903313471 hasRelatedWork W2116999983 @default.
• W2903313471 hasRelatedWork W2590971737 @default.
• W2903313471 hasRelatedWork W4297957154 @default.
• W2903313471 hasVolume "4" @default.
• W2903313471 isParatext "false" @default.
• W2903313471 isRetracted "false" @default.
• W2903313471 magId "2903313471" @default.
• W2903313471 workType "article" @default.